Intravenous Dexamethasone for Ropivacaine Axillary Block

Intravenous Dexamethasone Versus Placebo for Ultrasound Guided Axillary Brachial Plexus Block With Ropivacaine: Randomised, Controlled, Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02862327

Acronym

ADEXA

Enrollment

Registered

2016-08-11

Start date

2016-12-01

Completion date

2017-09-16

Last updated

2018-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain, Anesthesia, Forearm Injuries

Keywords

anaesthetic techniques, regional anesthesia, brachial plexus block, Local Anesthetic, ropivacaine, analgesia, steroid, dexamethasone, placebo, adjuvant, ultrasound guided

Brief summary

Prospective monocentric double-blind controlled randomised trial Aim is to assess prolonged postsurgical analgesia by intravenous dexamethasone versus intravenous placebo, after ultrasound guided axillary brachial plexus block

Interventions

DRUGintravenous dexamethasone

intravenous injection of dexamethasone

DRUGintravenous placebo

intravenous injection of placebo

DRUGperineural ropivacaine

brachial plexus block with perineural injection of Ropivacaine in the axillary fossa

OTHERultrasound guidance

ultrasound guidance for brachial plexus block in the axillary fossa

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ASA 1,2 et 3 * surgery under axillary brachial plexus block * aged \>18 years * signed information consent

Exclusion criteria

* impaired coagulation * contraindication to regional anesthesia or technical impossibility * opioids or pain killers abuse or addiction * steroids consumption in the past 6 months * dementia or under administrative supervision * delay of surgery to short to allow regional anesthesia * pregnancy and breastfeeding * allergy and contraindication to dexamethasone or ropivacaine * anticipated bad observation of treatment * patient enrolled in another trial

Design outcomes

Primary

Measure	Time frame
Analgesia duration after axillary brachial plexus block	time to first pain at surgical site, an average of 24 hours

Secondary

Measure	Time frame
Motor block duration after axillary brachial plexus block Safety	up to block recovery, an average of 24 hours
Sensory block duration after axillary brachial plexus block	up to block recovery, an average of 24 hours
incidence of adverse event	6 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026